AVITA Medical Inc (ASX: AVH) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
AVITA Medical Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...
See The 5 Stocks *Returns as of 9 January 2025
AVITA Medical Inc (ASX: AVH)
Latest News
Share Fallers
Why Avita Medical, Cettire, Domino's Pizza, and Star shares are falling today
Share Fallers
Why Avita Medical, Netwealth, Peninsula Energy, and Zip shares are sinking today
Share Fallers
Why did this ASX All Ords stock just crash 16%?
Cheap Shares
3 struggling ASX shares to buy at a discount
Growth Shares
2 ASX growth stocks that could turn $10,000 into $30,000 by 2030
Cheap Shares
Have $500? 2 absurdly cheap ASX shares I think long-term investors should buy right now
Share Fallers
Why Avita Medical, Deep Yellow, Piedmont Lithium, and Syrah shares are falling today
Investing Strategies
How I'd invest $40k to create a lifelong passive income of $36,000 a year
Share Gainers
Why Avita Medical, Core Lithium, Silex, and South32 shares are storming higher today
Healthcare Shares
3 ASX healthcare shares that could make you a millionaire
Investing Strategies
Investing in these 3 ASX shares now could make you a millionaire retiree
Investing Strategies
The 3 best deals on the ASX today
Frequently Asked Questions
-
No, AVITA Medical does not pay dividends at this time.
-
AVITA Medical Inc listed on the ASX on 24 June 2020.
-
Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.
AVH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|
About AVITA Medical Inc
AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.
The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993.
RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo.
AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.
AVH Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Jan 2025 | $2.84 | $0.04 | 1.43% | 350,923 | $2.80 | $2.85 | $2.74 |
17 Jan 2025 | $2.80 | $-0.06 | -2.10% | 508,782 | $2.82 | $2.83 | $2.74 |
16 Jan 2025 | $2.86 | $0.00 | 0.00% | 245,622 | $2.92 | $2.92 | $2.85 |
15 Jan 2025 | $2.86 | $-0.04 | -1.38% | 234,783 | $2.87 | $2.93 | $2.85 |
14 Jan 2025 | $2.90 | $-0.09 | -3.01% | 442,645 | $2.94 | $2.95 | $2.85 |
13 Jan 2025 | $2.99 | $-0.07 | -2.29% | 531,540 | $3.04 | $3.04 | $2.96 |
10 Jan 2025 | $3.06 | $0.01 | 0.33% | 692,206 | $3.06 | $3.15 | $3.05 |
09 Jan 2025 | $3.05 | $-0.46 | -13.11% | 1,918,273 | $2.95 | $3.15 | $2.89 |
08 Jan 2025 | $3.51 | $-0.84 | -19.31% | 2,205,923 | $3.92 | $3.92 | $3.47 |
07 Jan 2025 | $4.35 | $0.09 | 2.11% | 115,722 | $4.31 | $4.40 | $4.30 |
06 Jan 2025 | $4.26 | $0.12 | 2.90% | 241,904 | $4.19 | $4.33 | $4.16 |
03 Jan 2025 | $4.14 | $-0.03 | -0.72% | 110,103 | $4.19 | $4.21 | $4.11 |
02 Jan 2025 | $4.17 | $-0.08 | -1.88% | 122,185 | $4.16 | $4.20 | $4.08 |
31 Dec 2024 | $4.25 | $-0.12 | -2.75% | 152,104 | $4.28 | $4.31 | $4.17 |
30 Dec 2024 | $4.37 | $-0.02 | -0.46% | 237,410 | $4.45 | $4.52 | $4.30 |
27 Dec 2024 | $4.39 | $0.45 | 11.42% | 741,139 | $4.16 | $4.42 | $4.16 |
24 Dec 2024 | $3.94 | $0.13 | 3.41% | 756,731 | $4.05 | $4.11 | $3.94 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
07 Jun 2024 | Louis (Lou) Panaccio | Exercise | 6,175 | $17,660 |
Conversion of securities. 9,200 Rights
|
07 Jun 2024 | Louis (Lou) Panaccio | Issued | 6,175 | $17,660 |
Conversion of securities.
|
07 Jun 2024 | Suzanne Crowe | Issued | 6,175 | $17,660 |
Conversion of securities.
|
07 Jun 2024 | Suzanne Crowe | Exercise | 6,175 | $17,660 |
Conversion of securities. 9,200 RSU
|
07 Jun 2024 | Jeremy Curnock-Cook | Issued | 6,175 | $17,660 |
Conversion of securities.
|
07 Jun 2024 | Jeremy Curnock-Cook | Exercise | 6,175 | $17,660 |
Conversion of securities. 9,200 RSU
|
07 Jun 2024 | Jan Reed | Exercise | 6,175 | $17,660 |
Conversion of securities. 12,091 RSU
|
07 Jun 2024 | Jan Reed | Issued | 6,175 | $17,660 |
Conversion of securities.
|
07 Jun 2024 | Cary Vance | Issued | 9,633 | $27,550 |
Conversion of securities.
|
07 Jun 2024 | Cary Vance | Exercise | 9,633 | $27,550 |
Conversion of securities. 16,116 Rights
|
07 Jun 2024 | Robert McNamara | Exercise | 9,633 | $27,550 |
Conversion of securities. 16,116 RSUs
|
07 Jun 2024 | Robert McNamara | Issued | 9,633 | $27,550 |
Conversion of securities.
|
06 Jun 2024 | Louis (Lou) Panaccio | Issued | 9,200 | $26,036 |
Issue of securities. 15,375 RSU
|
06 Jun 2024 | Louis (Lou) Panaccio | Issued | 3,943 | $11,158 |
Issue of options.
|
06 Jun 2024 | Robert McNamara | Issued | 9,200 | $26,036 |
Issue of securities. 25,749 RSU
|
06 Jun 2024 | Robert McNamara | Issued | 3,943 | $11,158 |
Issue of options.
|
06 Jun 2024 | James Corbett | Issued | 350,000 | $990,500 |
Issue of options.
|
06 Jun 2024 | Cary Vance | Issued | 9,200 | $26,036 |
Issue of securities. 25,749 RSU
|
06 Jun 2024 | Cary Vance | Issued | 3,943 | $11,158 |
Issue of options.
|
06 Jun 2024 | Jan Reed | Issued | 9,200 | $26,036 |
Issue of securities. 18,266 RSU
|
06 Jun 2024 | Jan Reed | Issued | 3,943 | $11,158 |
Issue of options.
|
06 Jun 2024 | Jeremy Curnock-Cook | Issued | 9,200 | $26,036 |
Issue of securities. 15,375 RSU
|
06 Jun 2024 | Jeremy Curnock-Cook | Issued | 3,943 | $11,158 |
Issue of options.
|
06 Jun 2024 | Suzanne Crowe | Issued | 3,943 | $11,158 |
Issue of options.
|
06 Jun 2024 | Suzanne Crowe | Issued | 9,200 | $26,036 |
Issue of securities. 15,375 RSU
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Louis (Lou) James Panaccio | Non-Executive ChairmanNon-Executive Director | Jul 2014 |
Mr Panaccio is a healthcare businessman with experience leading companies from concept to commercialization. Mr. Panaccio possesses more than 35 years of executive leadership experience in healthcare services and life sciences, including more than 25 years of board-level experience. Mr Panaccio is currently a Director of ASX50 company and one of the medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005.
|
Professor Suzanne Crowe | Non-Executive Director | Jan 2016 |
Ms Crowe is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, and Emeritus Professor, Monash University Melbourne, she is currently a Director of Sonic Healthcare Ltd, a global medical diagnostics company. Past board positions include St Vincent's Health Australia Ltd (2012-2021), the country's not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research, and education.
|
Mr Jeremy Curnock-Cook | Non-Executive Director | Oct 2012 |
Mr Curnock-Cook is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr Curnock Cook brings his decades of international experience to our Board of Directors. Over his career, Mr Curnock Cook has managed more than US $1bn in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and investor in the sector. In his early career he founded the International Biochemicals Group which he sold to Royal Dutch Shell.
|
Dr Michael S Perry | Chief Executive Officer | Feb 2013 |
Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.
|
Ms Jan Stern Reed | Non-Executive Director | Jul 2021 |
Jan Stern Reed has served as a Non-Executive Director since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
|
Mr Cary Vance | Non-Executive Director | Apr 2023 |
Mr Vance has over 25 years of leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of PhotoniCare, Inc., a position he has held since May 2023. Prior to this appointment, he was President and CEO of Titan Medical, and he continues to serve as an independent director for Titan Medical's Board of Directors. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical.
|
Mr Robert McNamara | Non-Executive Director | Apr 2023 |
Mr McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine.
|
Mr Mark Andrew Licciardo | Company Secretary | Mar 2018 |
-
|
Mr James Corbett | Chief Executive OfficerPresident | Jul 2021 |
-
|
Ms Nicole Linda Kelsey | Chief Legal and Compliance OfficerCompany Secretary | Jul 2024 |
-
|
James Corbett | Chief Executive OfficerPresident |
-
|
|
David O'Toole | Chief Financial Officer |
-
|
|
Nicole Linda Kelsey | Chief Legal and Compliance OfficerCompany Secretary |
-
|
|
Mark Andrew Licciardo | Company Secretary |
-
|
|
Donna Shiroma | General Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
UBS Nominees Pty Ltd | 417,970 | 1.63% |
Citicorp Nominees Pty Limited | 400,634 | 1.56% |
Washington H Soul Pattinson And Company Limited | 302,529 | 1.18% |
BNPP Noms Pty Ltd HUB24 Custodial Serv Ltd | 285,593 | 1.11% |
P Morgan Nominees Australia Pty Limited | 204,641 | 0.80% |
Mr Evan Philip Clucas and Ms Leanne Jane Weston Kuranga Nursery Super A/C> | 159,013 | 0.62% |
Hsbc Custody Nominees (Australia) Limited | 122,390 | 0.48% |
Merrill Lynch (Australia) Nominees Pty Limited | 97,530 | 0.38% |
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 92,521 | 0.36% |
Bnp Paribas Noms Pty Ltd | 90,998 | 0.35% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 85,911 | 0.33% |
Taggart Investments Pty Ltd <Taggart Investment A/C> | 76,800 | 0.30% |
Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> | 63,116 | 0.25% |
Mr Eduard Avetisov | 62,060 | 0.24% |
Bnp Paribas Nominees Pty Ltd Acf Clearstream | 61,873 | 0.24% |
Mr Andre Wall Ellis and Mrs Olivia Louise Ellis | 60,000 | 0.23% |
Mrs Arlene Perry | 60,000 | 0.23% |
Wairahi Investments Limited | 60,000 | 0.23% |
Sandhurst Trustees Ltd <Jmfg Consol A/C> | 55,740 | 0.22% |
Mr David Anthony Deelen | 50,800 | 0.20% |